Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 20, Issue 2, Pages 241-246Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2008.04.008
Keywords
-
Categories
Funding
- NCI NIH HHS [P30 CA054174-16, CA100425, R01 CA100425-04, CA105207, CA054174, R01 CA105207-04, R01 CA100425, P30 CA054174, R01 CA105207] Funding Source: Medline
- FDA HHS [FD003118, R01 FD003118] Funding Source: Medline
- FOOD AND DRUG ADMINISTRATION [R01FD003118] Funding Source: NIH RePORTER
- NATIONAL CANCER INSTITUTE [R01CA100425, R01CA105207, P30CA054174] Funding Source: NIH RePORTER
Ask authors/readers for more resources
CD4+CD25+FOXP3+ regulatory T cells (Tregs) are elevated in cancers and can thwart protective antitumor immunity. Recent human cancer trials suggest that depleting Tregs can be clinically beneficial. Additional types of deleterious regulatory cells are also increased in cancer. Tregs also play unanticipated roles in cancer therapy in that some drugs unexpectedly increase (e.g. cancer vaccines or IL-2 treatment) or decrease (e.g. antineoangiogenesis agents or receptor tyrosine kinase inhibitors) their numbers or function. Managing deleterious effects of regulatory cells represents a novel and potentially effective way to give immunotherapy for cancer. New insights into molecular mechanisms governing trafficking, differentiation, and function of these cells suggest novel approaches to manipulating them as treatment strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available